Trial Profile
Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 16 Nov 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.